Vikas Sinha

Filings by Vikas Sinha span 4 companies, the busiest being Kalaris Therapeutics, Inc., Alexion Pharmaceuticals Inc and Verona Pharma plc. Over a trading history stretching from 4 February 2016 to 16 April 2026, the count stands at 61 filings.

Sales make up the whole of the open-market record (48 sales, €1.3M). The amount is not disclosed for 11 filings. The rest of the record consists of 8 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 2 sales.

On 20 April 2026 came the latest disclosure, an open-market sale for €438k in Scholar Rock Holding Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.